Mindray Announces First Quarter 2009 Financi...(5 Net revenues ...),Health
Navigation Links
Mindray Announces First Quarter 2009 Financial Results
Date:5/11/2009
5 Net revenues 87,428 134,165 Cost of revenues (note 2) (38,002) (59,424) Gross profit 49,426 74,741 Selling expenses (note 2) (10,484) (21,789) General and administrative expenses (note 2) (2,620) (8,797) Research and development expenses (note 2) (8,422) (14,745) Operating income 27,900 29,410 Other income (loss), net 502 (432) Interest income 2,358 1,620 Interest expense (5) (1,025) Income before income taxes and minority interests 30,755 29,573 Provision for income taxes (5,703) (4,232) Minority interests -- -- Net Income 25,052 25,341 Basic earnings per share 0.23 0.23 Diluted earnings per share 0.22 0.23 Shares used in the computation of: Basic earnings per share 106,962,659 107,872,202 Diluted earnings per share 112,998,260 112,118,964 (2) Share-based compensation charges incurred during the period related to: Cost of revenues 110 131 Selling expenses 805 1,051 General and administrative expenses 571 953 Research and development expenses
'/>"/>
| SOURCE Mindray Medical International Limited Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
2. Mindray to Report First Quarter 2009 Financial Results on May 11, 2009
3. Mindray Medical to Exhibit New Products at 61st China International Medical Equipment Fair
4. Mindray Announces Option Exchange Offer
5. Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009
6. Mindray Medical Achieves 2008 Product Development Goals and Announces Strong Pipeline for 2009
7. Mindray Announces Preliminary 2008 Operating Results
8. Mindray Medical to Present at the 27th Annual J.P. Morgan Healthcare Conference
9. Mindray Medical to Exhibit at RSNA 2008 in Chicago, from November 30th to December 4th, 2008
10. Mindray Announces 2008 Third Quarter and Nine Months Results
11. Mindray to Report Third Quarter 2008 Financial Results on November 11, 2008
Post Your Comments:
(Date:11/9/2009)...se action backs President Obama,s promise to not e...ample ,, Bishops still concerned for poor, el...wire/ -- Cardinal Francis George of Chicago, presi...ishops, lauded the November 7 decision of the U.S....care reform money from paying for elective abortio...
(Date:11/9/2009)...ped men and women almost equally, study finds, ,... widely used clot-dissolving drug Plavix (clopidog...nalysis of major clinical trials has found. , "... treating both men and women with this very import... cardiovascular thrombosis at New York University ...
(Date:11/9/2009)... improve letter formation could boost self-esteem,...lthDay News) -- Autistic children are more likely ...rming letters, than those without autism, research...aged 8 to 13. Half of the study participants had a...cored within the normal range for perceptual reaso...
(Date:11/9/2009)...ZHEN, China, Nov. 9 /PRNewswire-FirstCall/ - Hard ... announced today that Novartis, a US$41 billion in...% stake in HTDS, H1N1 Vaccine partner, Zhejiang Ti...llion. Novartis of Switzerland will begin a five-y...e company will dramatically increase its investmen...
(Date:11/9/2009)... New study highlights positive infl... Rosemont, IL (Vocus) Novembe...bone health decreases. Recent research has highlig...ments to help prevent these issues. However, a new... Sports Health: A Multidisciplinary Approach rev...
Breaking Medicine News(10 mins):Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 2Health News:Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly 3Health News:No Gender Gap Found for Clot-Busting Drug 2Health News:No Gender Gap Found for Clot-Busting Drug 3Health News:Handwriting Skills May Lag in Kids With Autism 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2[0] Cardinal George Lauds House Action to Ban Federal Funds for Abortion; Promises Vigilance as Senate Pursues Health Care Reform, Wary About Affect on Poor, Elderly[0] No Gender Gap Found for Clot-Busting Drug[0] Handwriting Skills May Lag in Kids With Autism[2] Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million[1] High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes
...xtend safety practices, CDC reports , , TH...ng for several years, reports of foodborne illness...ce 2004, federal health officials said Thursday. ,...all number of foodborne infections by 2010. , "Foo...
... 10, 2008) Carotid artery stenting is an effecti...ble for surgery, according to a long-term study pu...ine. Carotid artery disease, which involves cloggi...estimated 200,000 Americans each year who would ot...
...o world-leading companies have,come together to cr...A-,cleared, clinically proven light therapy techno...ate skin in the face and neck areas., (Logo: htt...ning beds, has partnered with Carlsbad, Calif.-,he...
...ers from the University of Pennsylvania School of ...signaling pathway, which determines the developmen...me cancers, is not universally essential for the m.... , Notch is one of a select set of proteins that...
... Surgery of the Head and Neck, NEW YORK, April 10...lizing in plastic and cosmetic surgery for the eth... Asian patients at a one day,Continuing Medical Ed..."Facial contouring, a commonly requested surgery a...
...nors and Mayors Support Event, ALEXANDRIA, Va., A...lthcare Decisions Day (NHDD), will be the largest,...rofessionals about,advance healthcare planning., ...e Decisions Day. "All Americans should use April 1...
Other Medicine News:Health News:Foodborne Illnesses Remain Constant in U.S. 2Health News:Foodborne Illnesses Remain Constant in U.S. 3Health News:SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery 2Health News:SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery 3Health News:Rejuvasun(TM) With Omnilux(TM): Industry First to Feature FDA-Cleared, Clinically Proven Light Therapy Technology 2Health News:Rejuvasun(TM) With Omnilux(TM): Industry First to Feature FDA-Cleared, Clinically Proven Light Therapy Technology 3Health News:Developing cancer treatments directed at critical developmental pathway 2Health News:Dr. Edmund Kwan to Speak on Facial Contouring Among Asian Patients at Cosmetic Surgery Seminar 2Health News:National Healthcare Decisions Day in All 50 States, DC, Puerto Rico, and Internationally 2Foodborne Illnesses Remain Constant in U.S.SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgeryRejuvasun(TM) With Omnilux(TM): Industry First to Feature FDA-Cleared, Clinically Proven Light Therapy TechnologyDeveloping cancer treatments directed at critical developmental pathwayDr. Edmund Kwan to Speak on Facial Contouring Among Asian Patients at Cosmetic Surgery SeminarNational Healthcare Decisions Day in All 50 States, DC, Puerto Rico, and Internationally
(Date:11/9/2009)..., WALTHAM, Mass., Nov. 9 Decisio...nd advisory firms for pharmaceutical and healthcar...wth factor receptor 2 (HER2) targeting therapies -...SmithKline/Nippon Kayaku,s Tykerb/Tyverb -- were t...atment. Continued uptake of Herceptin and Tykerb/T...
(Date:11/9/2009)..., SUNNYVALE, Calif., Nov. 9 /PRNewswire-FirstCal...harmaceutical company focused on developing and co...the treatment of immune mediated diseases and canc...sident, Preclinical Development will provide an ov... Merriman Curhan Ford,s 6th Annual Investor Summit...
(Date:11/9/2009)..., GLEN ROCK, Pa., Nov. 9 ARmark ...c. announced today an alliance in the development ...M) , an authentication technology that incorporate...-release film coatings of solid oral dosage forms ...ovides Colorcon exclusive rights to market ARmark,...
Breaking Medicine Technology:Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018 2Pharmacyclics to Present at Merriman Curhan Ford's Investor Summit 2009 2ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance 2ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance 3Study reveals new role of vitamin C in skin protection 56591 1Study reveals new role of vitamin C in skin protection 56591 2UAB researchers find TB prevention therapy is cost effective option 56588 1UAB researchers find TB prevention therapy is cost effective option 56588 2Lead in bone associated with increased risk of death from cardiovascular disease in men 56585 1Lead in bone associated with increased risk of death from cardiovascular disease in men 56585 2...ng and Webcast to Follow,Presentation, DANBURY, Co...l,Inc. today announced plans to present clinical r...M), at the 67th Annual American,Diabetes Associati...o, June 22 through June 26. , Biodel,s oral presen...4:15 - 6:15pm CST, a summary of which will be avai...
...wire-FirstCall/ -- Orexigen(TM),Therapeutics, Inc....tment of central nervous system disorders with an ... Company will present data,about its lead obesity ...arkers of cardiovascular disease (visceral fat, se...sistance. The,findings come from additional analys...
Other Medicine Technology:Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 2Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 3Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23 2Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23 3AQuify Long-Lasting Comfort Drops
Lens Plus Rewetting Drops
Renu Rewetting Drops
Renu Multiplus Lubricating and Rewetting Drops
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |